Generalized myasthenia gravis patients infected with COVID-19 should continue eculizumab

Authors :: Masahiro Mimori
Teppei Komatsu
Takahiro Maku
Hidetaka Mitsumura
Yasuyuki Iguchi
Source :: Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology. 43(7)
Publication Year :: 2022
Abstract: Eculizumab, a humanized monoclonal antibody, is a complement inhibitor indicated for refractory generalized myasthenia gravis (MG). However, there are limited data on the safety of eculizumab for MG during coronavirus disease 2019 (COVID-19) infection. We report a case in which eculizumab was continued for MG after contracting COVID-19, followed by a favorable outcome.

Subjects :: Psychiatry and Mental health
Complement Inactivating Agents
Myasthenia Gravis
COVID-19
Humans
Neurology (clinical)
Dermatology
General Medicine
Antibodies, Monoclonal, Humanized

ISSN :: 15903478
Volume :: 43
Issue :: 7
Database :: OpenAIRE
Journal :: Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology
Accession number :: edsair.doi.dedup.....947edd5a794ced0e056c9b1bd82935cb

Tools